gadodiamide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
diagnostic agents, gadolinium derivatives 4494 131410-48-5

Description:

MoleculeDescription

Synonyms:

  • omniscan
  • gadodiamide
for intravenous administration with MRI in adult patients for contrast enhancement of CNS lesions
  • Molecular weight: 573.66
  • Formula: C16H26GdN5O8
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 0.20 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.79 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.46 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 8, 1993 FDA GE HEALTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nephrogenic systemic fibrosis 2174.70 52.95 346 2608 3976 50598194
Skin hypertrophy 402.61 52.95 79 2875 3016 50599154
Skin induration 401.28 52.95 78 2876 2833 50599337
Skin tightness 305.79 52.95 65 2889 3698 50598472
Fibrosis 195.26 52.95 45 2909 3702 50598468
Skin fibrosis 194.45 52.95 35 2919 824 50601346
Skin hyperpigmentation 150.37 52.95 39 2915 5237 50596933
Joint range of motion decreased 147.07 52.95 51 2903 18461 50583709
Joint contracture 108.14 52.95 24 2930 1660 50600510
Scar 103.32 52.95 35 2919 11783 50590387
Emotional distress 92.09 52.95 41 2913 28622 50573548
Skin discolouration 89.94 52.95 42 2912 32715 50569455
Anhedonia 78.51 52.95 27 2927 9497 50592673
Peau d'orange 75.03 52.95 12 2942 134 50602036
Joint stiffness 74.44 52.95 36 2918 30272 50571898
Mobility decreased 73.59 52.95 50 2904 79898 50522272
Oedema peripheral 69.73 52.95 64 2890 157897 50444273
Erythema 67.90 52.95 61 2893 146353 50455817
Skin plaque 64.29 52.95 21 2933 6307 50595863
Deformity 63.46 52.95 22 2932 7918 50594252
Pain 62.03 52.95 116 2838 578787 50023383
Muscle contracture 60.19 52.95 14 2940 1193 50600977
Extremity contracture 59.72 52.95 14 2940 1234 50600936
Magnetic resonance imaging head abnormal 54.81 52.95 14 2940 1763 50600407

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nephrogenic systemic fibrosis 2272.46 49.28 386 2768 3556 29567817
Skin hypertrophy 374.99 49.28 79 3075 2324 29569049
Skin tightness 355.38 49.28 73 3081 1891 29569482
Skin induration 352.12 49.28 73 3081 1981 29569392
Joint range of motion decreased 240.72 49.28 66 3088 5988 29565385
Joint contracture 234.30 49.28 51 3103 1749 29569624
Skin fibrosis 215.08 49.28 43 3111 964 29570409
Fibrosis 178.61 49.28 43 3111 2316 29569057
Scar 165.07 49.28 48 3106 5371 29566002
Extremity contracture 131.26 49.28 27 3127 699 29570674
Deformity 128.05 49.28 30 3124 1434 29569939
Emotional distress 124.27 49.28 49 3105 13846 29557527
Mobility decreased 122.08 49.28 58 3096 25722 29545651
Joint stiffness 112.10 49.28 41 3113 9432 29561941
Anhedonia 103.48 49.28 36 3118 7164 29564209
Pain 87.56 49.28 99 3055 171333 29400040
Oedema peripheral 84.27 49.28 77 3077 103480 29467893
Injury 81.47 49.28 40 3114 19006 29552367
Skin disorder 70.19 49.28 31 3123 11587 29559786
Skin discolouration 67.79 49.28 33 3121 15376 29555997
Musculoskeletal stiffness 65.82 49.28 44 3110 37414 29533959
Skin hyperpigmentation 64.00 49.28 20 3134 2844 29568529
Anxiety 53.37 49.28 55 3099 85310 29486063

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nephrogenic systemic fibrosis 3059.04 52.38 500 4191 5392 64488649
Skin hypertrophy 607.44 52.38 123 4568 4406 64489635
Skin induration 581.39 52.38 117 4574 4058 64489983
Skin tightness 520.84 52.38 110 4581 4851 64489190
Skin fibrosis 314.40 52.38 59 4632 1400 64492641
Joint range of motion decreased 294.89 52.38 92 4599 19251 64474790
Joint contracture 263.79 52.38 55 4636 2264 64491777
Fibrosis 240.12 52.38 58 4633 4670 64489371
Scar 192.70 52.38 61 4630 13337 64480704
Biopsy brain abnormal 172.38 52.38 21 4670 8 64494033
Skin hyperpigmentation 169.51 52.38 47 4644 6504 64487537
Joint stiffness 143.94 52.38 61 4630 30343 64463698
Oedema peripheral 135.40 52.38 116 4575 210201 64283840
Mobility decreased 130.87 52.38 80 4611 85760 64408281
Skin discolouration 128.93 52.38 59 4632 35196 64458845
Emotional distress 127.69 52.38 59 4632 35979 64458062
Deformity 121.71 52.38 36 4655 6261 64487780
Anhedonia 120.05 52.38 43 4648 13663 64480378
Extremity contracture 114.42 52.38 26 4665 1599 64492442
Peau d'orange 102.40 52.38 18 4673 291 64493750
Skin disorder 100.15 52.38 46 4645 27634 64466407
Pain 95.65 52.38 155 4536 553356 63940685
Erythema 84.89 52.38 85 4606 186985 64307056
Muscle contracture 82.15 52.38 21 4670 2124 64491917
Skin plaque 81.87 52.38 29 4662 8911 64485130
Injury 74.69 52.38 48 4643 55944 64438097
Musculoskeletal stiffness 73.10 52.38 65 4626 123141 64370900
Magnetic resonance imaging head abnormal 65.57 52.38 18 4673 2394 64491647
Pruritus 64.19 52.38 95 4596 312305 64181736
Muscle tightness 61.66 52.38 25 4666 11090 64482951
Skin exfoliation 61.14 52.38 39 4652 44846 64449195
Anxiety 58.90 52.38 73 4618 202576 64291465
Pain of skin 58.25 52.38 23 4668 9524 64484517
Muscular weakness 57.92 52.38 58 4633 127280 64366761
Magnetic resonance imaging abnormal 56.62 52.38 17 4674 3106 64490935
Gait disturbance 56.54 52.38 66 4625 172089 64321952
Dry skin 54.14 52.38 38 4653 51123 64442918

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC V08CA03 VARIOUS
CONTRAST MEDIA
MAGNETIC RESONANCE IMAGING CONTRAST MEDIA
Paramagnetic contrast media
MeSH PA D003287 Contrast Media
MeSH PA D064907 Diagnostic Uses of Chemicals
FDA MoA N0000175862 Magnetic Resonance Contrast Activity
FDA EPC N0000180184 Paramagnetic Contrast Agent

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Magnetic resonance imaging indication 113091000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D04284 KEGG_DRUG
4020689 VUID
N0000148302 NUI
4020689 VANDF
CHEBI:31642 CHEBI
CHEMBL1200346 ChEMBL_ID
C064925 MESH_SUPPLEMENTAL_RECORD_UI
6636 INN_ID
DB00225 DRUGBANK_ID
84F6U3J2R6 UNII
60754 PUBCHEM_CID
41144 RXNORM
10205 MMSL
4771 MMSL
d04083 MMSL
004259 NDDF
354088005 SNOMEDCT_US
396067007 SNOMEDCT_US
C0082646 UMLSCUI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
OMNISCAN HUMAN PRESCRIPTION DRUG LABEL 1 0407-0690 INJECTION 287 mg INTRAVENOUS NDA 28 sections
OMNISCAN HUMAN PRESCRIPTION DRUG LABEL 1 0407-0690 INJECTION 287 mg INTRAVENOUS NDA 28 sections
OMNISCAN HUMAN PRESCRIPTION DRUG LABEL 1 0407-0690 INJECTION 287 mg INTRAVENOUS NDA 28 sections
OMNISCAN HUMAN PRESCRIPTION DRUG LABEL 1 0407-0691 INJECTION 287 mg INTRAVENOUS NDA 28 sections